Category Archives: News

Clarity expands manufacturing capabilities for its Cu-64 SAR-bisPSMA clinical programs

Sydney, Australia 11 August 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, has signed a supply agreement with 3D Imaging LLC. (3DI), a Contract Development and Manufacturing Organisation (CDMO), covering Clarity’s diagnostic 64Cu SAR-bisPSMA product. The new agreement, effective on August 11th, 2022,…

Clarity and Evergreen expand Targeted Copper Theranostics manufacturing

Sydney, Australia 9 August 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, and Evergreen Theragnostics, Inc. (“Evergreen”), a radiopharmaceutical contract development and manufacturing organisation, are pleased to announce that the companies have expanded their Targeted Copper Theranostics (TCTs) manufacturing agreement to include next-generation…

Recruitment complete for Clarity’s PROPELLER prostate cancer diagnostic trial

Sydney, Australia 20 July 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce the completion of recruitment for the Phase I PROPELLER diagnostic trial evaluating its 64Cu-SAR-bisPSMA product candidate in patients with untreated, confirmed prostate cancer, scheduled for radical prostatectomy.…

Leading Australian cancer expert joins Clarity’s Scientific Advisory Board

Sydney, Australia 29 June 2022 Highlights Professor Louise Emmett joins Clarity’s Scientific Advisory Board (SAB) She is deeply embedded in Australia’s multidisciplinary clinical development and cancer research efforts Professor Emmett will continue to be highly active and influential in progressing Clarity’s SAR Technology as both a collaborator and now as a SAB member Follows the…

IND approval from the US FDA for Phase II SAR-Bombesin imaging trial in prostate cancer

Sydney, Australia 6 June 2022 Highlights IND approval received for SAR-Bombesin product, enabling a Phase II “SABRE” imaging trial to detect prostate cancer in up to 50 PSMA-negative participants in the US Approximately 20% of prostate cancer patients with biochemical recurrence are PSMA-PET negative and therefore unsuitable for the currently approved PSMA targeting agents, presenting…

Clarity adds innovative nanobody IP to its Discovery pipeline

Sydney, Australia 31 May 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce the acquisition of a targeted nanobody platform to its Discovery pipeline. The intellectual property, including a provisional patent and know-how, has been acquired from leading nanotechnology researcher…

Dr Neal Shore joins Clarity’s Clinical Advisory Board

Sydney, Australia 26 May 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that Dr Neal Shore has joined Clarity’s Clinical Advisory Board (CAB). Dr Shore MD, FACS is the Chief Medical Officer of Urology/Surgical Oncology at GenesisCare, US and…

Clarity confirms no supply issues to its ongoing clinical trials programs

Sydney, Australia 5 May 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, confirms Clarity and its clinical development programs are unaffected by Novartis’ recent suspension of production of Lutathera® and Pluvicto™/ 177Lu-PSMA-617 at its facilities in Ivrea, Italy and Millburn, New Jersey. On…

First patient treated in the US-based prostate cancer imaging trial of Cu-64 SAR-bisPSMA

Sydney, Australia 21 April 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that it has successfully treated its first participant in the diagnostic US-based 64Cu SAR-bisPSMA trial for patients with biochemical recurrence (BCR) of prostate cancer. COBRA (Copper-64 SAR-bisPSMA in Biochemically Recurrent…

Dr Andrei Iagaru joins Clarity’s Scientific Advisory Board

Sydney, Australia 5 April 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that Dr Andrei Iagaru has joined Clarity’s Scientific Advisory Board (SAB). Dr Iagaru is a Professor of Radiology – Nuclear Medicine and the Chief of the Division of…